GlaxoSmithKline Historical Cash Flow

GSK Stock  USD 42.87  0.12  0.28%   
Analysis of GlaxoSmithKline PLC cash flow over time is an excellent tool to project GlaxoSmithKline PLC ADR future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Depreciation of 1.4 B or Other Non Cash Items of 567 M as it is a great indicator of GlaxoSmithKline PLC ability to facilitate future growth, repay debt on time or pay out dividends.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Financial Statement Analysis is much more than just reviewing and examining GlaxoSmithKline PLC ADR latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether GlaxoSmithKline PLC ADR is a good buy for the upcoming year.
  
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.

About GlaxoSmithKline Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in GlaxoSmithKline balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which GlaxoSmithKline's non-liquid assets can be easily converted into cash.

GlaxoSmithKline PLC Cash Flow Chart

GlaxoSmithKline Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the GlaxoSmithKline PLC ADR Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, GlaxoSmithKline PLC's Other Non Cash Items is quite stable compared to the past year. Stock Based Compensation is expected to rise to about 335.4 M this year, although the value of Free Cash Flow will most likely fall to about 3.4 B.

Free Cash Flow

The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by GlaxoSmithKline PLC ADR to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of GlaxoSmithKline PLC operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Net Income

Net income is one of the most important fundamental items in finance. It plays a large role in GlaxoSmithKline PLC ADR financial statement analysis. It represents the amount of money remaining after all of GlaxoSmithKline PLC ADR operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.
Most accounts from GlaxoSmithKline PLC's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into GlaxoSmithKline PLC ADR current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
At this time, GlaxoSmithKline PLC's Other Non Cash Items is quite stable compared to the past year. Stock Based Compensation is expected to rise to about 335.4 M this year, although the value of Free Cash Flow will most likely fall to about 3.4 B.

GlaxoSmithKline PLC cash flow statement Correlations

0.370.230.480.1-0.180.20.090.180.330.440.120.060.050.220.110.06-0.270.16
0.370.020.23-0.34-0.18-0.02-0.220.470.340.390.110.210.28-0.260.41-0.440.050.23
0.230.02-0.040.450.40.440.540.140.480.47-0.40.48-0.480.54-0.50.53-0.19-0.23
0.480.23-0.04-0.07-0.09-0.130.120.050.060.320.180.32-0.12-0.010.16-0.1-0.10.12
0.1-0.340.45-0.070.410.660.540.220.77-0.09-0.060.20.080.060.090.08-0.340.15
-0.18-0.180.4-0.090.410.290.680.060.280.36-0.410.5-0.380.020.03-0.020.01-0.14
0.2-0.020.44-0.130.660.290.390.340.680.22-0.210.380.370.050.15-0.01-0.260.09
0.09-0.220.540.120.540.680.390.220.390.18-0.220.74-0.19-0.10.06-0.010.09-0.46
0.180.470.140.050.220.060.340.220.570.070.360.360.35-0.570.42-0.580.48-0.28
0.330.340.480.060.770.280.680.390.570.170.020.370.27-0.140.37-0.24-0.260.26
0.440.390.470.32-0.090.360.220.180.070.17-0.380.47-0.340.36-0.070.09-0.10.01
0.120.11-0.40.18-0.06-0.41-0.21-0.220.360.02-0.38-0.250.2-0.370.17-0.270.47-0.2
0.060.210.480.320.20.50.380.740.360.370.47-0.25-0.05-0.220.22-0.240.15-0.38
0.050.28-0.48-0.120.08-0.380.37-0.190.350.27-0.340.2-0.05-0.580.72-0.62-0.130.33
0.22-0.260.54-0.010.060.020.05-0.1-0.57-0.140.36-0.37-0.22-0.58-0.790.92-0.510.17
0.110.41-0.50.160.090.030.150.060.420.37-0.070.170.220.72-0.79-0.920.050.32
0.06-0.440.53-0.10.08-0.02-0.01-0.01-0.58-0.240.09-0.27-0.24-0.620.92-0.92-0.39-0.06
-0.270.05-0.19-0.1-0.340.01-0.260.090.48-0.26-0.10.470.15-0.13-0.510.05-0.39-0.77
0.160.23-0.230.120.15-0.140.09-0.46-0.280.260.01-0.2-0.380.330.170.32-0.06-0.77
Click cells to compare fundamentals

GlaxoSmithKline PLC Account Relationship Matchups

GlaxoSmithKline PLC cash flow statement Accounts

201920202021202220232024 (projected)
Change To Inventory300M119M25M(269M)(424M)(402.8M)
Change In Cash744M431M(1.4B)(394M)(787M)(747.7M)
Free Cash Flow5.9B6.2B5.0B5.1B4.0B3.4B
Change In Working Capital531M120M(473M)271M(856M)(813.2M)
Begin Period Cash Flow4.1B4.8B5.3B3.8B3.7B2.2B
Other Cashflows From Financing Activities(194M)122M27M8.9B(78M)(74.1M)
Depreciation3.0B624M2.5B2.3B2.3B1.4B
Other Non Cash Items814M848M756M(433M)540M567M
Capital Expenditures2.2B2.2B2.9B2.3B2.3B1.5B
Total Cash From Operating Activities8.0B8.4B8.0B7.4B6.3B4.9B
Net Income5.3B6.4B5.1B4.9B4.9B4.6B
Total Cash From Financing Activities(1.8B)(10.1B)(7.6B)823M(4.9B)(4.6B)
End Period Cash Flow4.8B5.3B3.8B3.4B2.9B2.1B
Dividends Paid4.0B4.0B4.0B3.5B(2.2B)(2.1B)
Sale Purchase Of Stock10.3B999M(1.6B)25M(197M)(206.9M)
Change To Account Receivables(953.8M)(224M)(782M)(158M)(649M)(681.5M)
Stock Based Compensation365M381M367M346M307M335.4M
Investments(5.4B)2.2B334M(8.8B)(1.6B)(1.5B)
Net Borrowings3.5B(4.2B)(2.2B)(4.8B)(5.5B)(5.8B)
Total Cashflows From Investing Activities(5.4B)2.2B(1.8B)(8.8B)(7.9B)(7.5B)
Change To Operating Activities(160M)(159M)1.3B(1.4B)(1.3B)(1.2B)
Change To Netincome670M380M105M(8.3B)(9.6B)(10.1B)
Change To Liabilities263M225M284M494M568.1M596.5M
Issuance Of Capital Stock51M29M21M25M10M9.5M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether GlaxoSmithKline PLC ADR is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if GlaxoSmithKline Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Glaxosmithkline Plc Adr Stock. Highlighted below are key reports to facilitate an investment decision about Glaxosmithkline Plc Adr Stock:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in GlaxoSmithKline PLC ADR. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in state.
You can also try the AI Investment Finder module to use AI to screen and filter profitable investment opportunities.

Complementary Tools for GlaxoSmithKline Stock analysis

When running GlaxoSmithKline PLC's price analysis, check to measure GlaxoSmithKline PLC's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline PLC is operating at the current time. Most of GlaxoSmithKline PLC's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline PLC's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline PLC's price. Additionally, you may evaluate how the addition of GlaxoSmithKline PLC to your portfolios can decrease your overall portfolio volatility.
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is GlaxoSmithKline PLC's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of GlaxoSmithKline PLC. If investors know GlaxoSmithKline will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about GlaxoSmithKline PLC listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.77)
Dividend Share
0.58
Earnings Share
3.02
Revenue Per Share
14.97
Quarterly Revenue Growth
0.092
The market value of GlaxoSmithKline PLC ADR is measured differently than its book value, which is the value of GlaxoSmithKline that is recorded on the company's balance sheet. Investors also form their own opinion of GlaxoSmithKline PLC's value that differs from its market value or its book value, called intrinsic value, which is GlaxoSmithKline PLC's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because GlaxoSmithKline PLC's market value can be influenced by many factors that don't directly affect GlaxoSmithKline PLC's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between GlaxoSmithKline PLC's value and its price as these two are different measures arrived at by different means. Investors typically determine if GlaxoSmithKline PLC is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, GlaxoSmithKline PLC's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.